We transform the most promising oncology innovations into highly competitive opportunities that benefit patients, researchers, investors, and Ontario's economy. Cancer Breakthroughs. Realized.
Home Carousel
FACIT Makes Follow-on Investment in AI-based genomics company, DNAstack
Capital leverages Ontario’s strengths in genomics and informatics, deepens FACIT’s tech portfolio
FACIT's Compass Rose Oncology Fund is providing the follow-on investment. DNAstack also previously received capital from FACIT's early-stage Prospects Oncology Fund, illustrating FACIT's strategy to ensure promising companies grow roots and scale up in Ontario.
FACIT Features: Portfolio company KA Imaging launches first-in-human pilot study to test lung screening x-ray
FACIT congratulates portfolio company KA Imaging on significant clinical development milestone.
KA Imaging, a recent Prospects Fund recipient, is partnering with Grand River Hospital to conduct a pilot study on the use of a high-resolution multi-energy digital x-ray imager for patients with lung nodules.
FACIT Welcomes Har Grover and Ken Lawless to the Board
Strategic appointments of seasoned entrepreneurs add expertise and strengthen governance
Both leaders are passionate supporters of the Ontario life science sector, have broad industry experience and decades of work with entrepreneurial ventures.
FACIT Invests in Three Top Ontario Entrepreneur-Teams from Near Record Pool of Applicants
Prospects Oncology Fund seeds developing pipeline of Ontario-based biotech innovations
With an expanding portfolio of breakthrough innovations, FACIT is committed to supporting Ontario entrepreneurs through the latest round of its Prospects Oncology Fund.
Healthcare Software Start-Up Ziliomics Financed by FACIT
World-leading genomics cloud computing group builds clinical tool for cancer care in Ontario
Derived from a leading oncology bio-computing group and leveraging insights from the world’s largest cancer genomics projects, Ziliomics develops web-based, modular software platforms that help physicians make actionable treatment decisions for patients living with cancer.
FACIT Appoints Biotech Veteran Dr. David O'Neill as President
Entrepreneur adds US oncology management experience to Ontario commercialization.
Dr O’Neill brings two decades of cancer drug development and seed stage investment experience, as well as an extensive business network in pharma and biotech.
as of March 2018
-
$340M
Leveraged funding associated with FACIT support.
-
$35M
Funding & equity investments.
-
43
Projects at Ontario institutions or Startups supported by FACIT funding.
-
14
Companies in Ontario created by FACIT investments.
Our Strategic Partner
FACIT also facilitates technology transfer, partnerships, and collaborations with the
Ontario Institute for Cancer Research >
